Search results for " benzodiazepine"

showing 5 items of 5 documents

GABAergic System in Action: Connection to Gastrointestinal Stress-related Disorders.

2017

Background: Currently, treatment of stress-related gastrointestinal disorders, such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), is mainly symptomatic since there is no drug on the market that solves effectively diverse disease symptoms and comorbid states. Thus, recently GABA receptors have been identified within gastrointestinal system and it has been recognized that among various GABAergic drugs some of them influence gastrointestinal stress-related diseases. Firstly, benzodiazepines have been investigated due to their diverse effects: neuroimmunomodulatory, relief of visceral pain and anxiolytic action. Conclusion: The present review brings findings on the exp…

0301 basic medicineStremedicine.drug_classGastrointestinal DiseasesGABAergic systemDiseasePharmacologyBioinformaticsSettore BIO/09 - FisiologiaAnxiolyticInflammatory bowel diseaseIrritable Bowel Syndrome03 medical and health sciencesBenzodiazepines0302 clinical medicineReceptors GABADrug DiscoverymedicineAnimalsHumansIrritable bowel syndromeGABAergic system ; stress ; benzodiazepines ; gastrointestinal system ; stress-related disorders ; therapygamma-Aminobutyric AcidPharmacologytherapyGastrointestinal tractbusiness.industryStress-related disordersVisceral painmedicine.diseaseInflammatory Bowel Diseases030104 developmental biologystress-related disordergastrointestinal systemGABAergic030211 gastroenterology & hepatologybenzodiazepinemedicine.symptombusinessStress PsychologicalCurrent pharmaceutical design
researchProduct

Diagnosis and therapeutic management of primary headache in an emergency setting

2013

Introduction and aim: Much headachers are under or mis-diagnoses and data regarding the proportion of patients attending an emergency department (ED) because of headache are still few. We conducted a retrospective observational study in an ED with the following aims: (a) estimate the proportion of headache attending to an ED (b) to estimate and describe the therapeutic management of primary headache and (c) to assessment the exam most frequently requested. Materials and methods: We collected data regarding patients diagnosed with headache consecutively attending the ED of the University of Palermo between September 2011 and March 2012. The study was approved by the ethics committee. Results: Between the semester evaluated 25110 subjects were admitted to ED headache suffers were equal to 1.6 %. Of these 263 (63.1 %) were woman and 154 (36.9 %). Mean age was 44.2 (DS ± 18.4) years (p = 0.068).According to ED registry headache admission was as follow assigned: 76.5 % with a diagnosis of headache 22.8 % with a secondary headache 0.7 % with Trigeminal Autonomic Cephalgias (TACs). Among those with a primary headache about 36 % of patient did not received a pharmacological treatment. Monotherapy was prescribed less frequently than combination therapy (19.1 vs 44.5 %).In monotherapy the most frequent medication were NSAIDs (28.3 %) benzodiazepines (26.7 %) and dopamine antagonists (11.7 %). Among those with a primary headache a CT scan was performed in the 124 subjects and 111 (34.8 %) had a neurologist consultation. Discussion: Our data are in line with the one previously reported in literature. The most frequently medication in the Italian ED were NSAIDs benzodiazepines dopamine antagonists and steroids. Neverless our data unlikely can be compared to other study give a snapshot. We believe that much more can be done to improve treatment of primary headache in ED.Settore MED/26 - Neurologia
researchProduct

Treatments used for obsessive-compulsive disorder-An international perspective.

2018

Objective The objective of this study was to characterise international trends in the use of psychotropic medication, psychological therapies, and novel therapies used to treat obsessive–compulsive disorder (OCD). Methods Researchers in the field of OCD were invited to contribute summary statistics on the characteristics of their samples. Consistency of summary statistics across countries was evaluated. Results The study surveyed 19 expert centres from 15 countries (Argentina, Australia, Brazil, China, Germany, Greece, India, Italy, Japan, Mexico, Portugal, South Africa, Spain, the United Kingdom, and the United States) providing a total sample of 7,340 participants. Fluoxetine (n = 972; 13…

MaleObsessive-Compulsive DisorderInternationalitymedicine.medical_treatmentDeep Brain StimulationSocial SciencesFluvoxamineBENZODIAZEPINASpharmacotherapyBenzodiazepines0302 clinical medicinePharmacology (medical)TERAPIA PSICOANALITICAPSICOFARMACOLOGIAantipsychotics; benzodiazepines; cross-cultural study; obsessive-compulsive disorder; pharmacotherapy; selective serotonin reuptake inhibitorsMiddle Aged3. Good healthExposure and response preventionantipsychotics; benzodiazepines; cross-cultural study; obsessive–compulsive disorder; pharmacotherapy; selective serotonin reuptake inhibitorsNeurologyPsychiatry and Mental HealthSerotonin Uptake Inhibitorscross-cultural studyAripiprazoleFemalebenzodiazepineSelective Serotonin Reuptake Inhibitorsmedicine.drugPsychosurgeryAntipsychotic AgentsAdultmedicine.medical_specialty:Ciências da Saúde [Ciências Médicas]Ciências Médicas::Ciências da SaúdeSerotonin reuptake inhibitor03 medical and health sciencesANTIPSICOTICOSobsessive–compulsive disorderselective serotonin reuptake inhibitorsmedicinePSICOTROPICOSHumansAntipsychoticPsychiatryFARMACOTERAPIAFluoxetineRisperidoneantipsychotics; benzodiazepines; cross-cultural study; obsessive–compulsive disorder; pharmacotherapy; selective serotonin reuptake inhibitors; Neurology; Neurology (clinical); Psychiatry and Mental Health; Pharmacology (medical)Science & Technologyselective serotonin reuptake inhibitorbusiness.industryTRASTORNO OBSESIVO COMPULSIVO030227 psychiatryantipsychoticPsychosurgeryantipsychoticsNeurology (clinical)business030217 neurology & neurosurgerySEROTONINAHuman psychopharmacology
researchProduct

Molecular dynamics studies on Mdm2 complexes: An analysis of the inhibitor influence

2012

p53 is a powerful anti-tumoral molecule frequently inactivated by mutations or deletions in cancer. However, half of all human tumors expresses wild-type p53, and its activation, by antagonizing its negative regulator Mdm2, might offer a new strategy for therapeutic protocol. In this work, we present a molecular dynamics study on Mdm2 structure bound to two different known inhibitors with the aim to investigate the structural transitions between apo-Mdm2 and Mdm2-inhibitor complexes. We tried to gain information about conformational changes binding a benzodiazepine derivative inhibitor with respect the known nutlin and the apo form. The conformational changes alter the size of the cleft and…

Protein ConformationBiophysicsMolecular Dynamics SimulationMdm2 p53 nutlin benzodiazepine Molecular DynamicsBiochemistryNegative regulatorBenzodiazepineschemistry.chemical_compoundMolecular dynamicsHumansMoleculeEnzyme InhibitorsMolecular BiologyBinding SitesbiologyChemistryProto-Oncogene Proteins c-mdm2Cell BiologyNutlinSettore CHIM/08 - Chimica FarmaceuticaBiochemistryDrug DesignBiophysicsbiology.proteinMdm2LinkerBiochemical and Biophysical Research Communications
researchProduct

Synthesis, benzodiazepine receptor binding and molecular modelling of isochromeno[4,3-c]pyrazol-5(1H)-one derivatives

2012

Abstract A series of isochromeno[4,3-c]pyrazole-5(1H)-one derivatives 7b–h were prepared and tested at 10 μM for their ability to displace specific [3H]flunitrazepam from bovine brain membranes. The substitution pattern of the above derivatives was shown to influence the receptor affinity. The most active compound of the series was 7e, showing a 54% inhibition of [3H]flunitrazepam binding. Compounds 7a–d,i were compared with the known isomers chromeno[4,3-c]pyrazole-4(1H)-ones 14a–d,i, showing that the isochromene/chromene isomerism influences the activity.

StereochemistryProtein ConformationChemistry Techniques SyntheticIsochromeno[43-c]pirazoles Dihydrospiro[isoindole-13’-pyrazol]-3(2H)- ones Benzodiazepine receptorDrug DiscoverymedicineAnimalsHumansBenzopyransReceptorBenzodiazepine receptor bindingPharmacologyChemistryOrganic ChemistryGeneral MedicineReceptors GABA-ASettore CHIM/08 - Chimica FarmaceuticaMolecular Docking SimulationMembraneBovine brainActive compoundPyrazolesCattleFlunitrazepam bindingFlunitrazepammedicine.drugProtein Binding
researchProduct